Dowling & Yahnke LLC Fate Therapeutics Inc Transaction History
Dowling & Yahnke LLC
- $215 Million
- Q3 2022
A detailed history of Dowling & Yahnke LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Dowling & Yahnke LLC holds 30,640 shares of FATE stock, worth $68,020. This represents 0.32% of its overall portfolio holdings.
Number of Shares
30,640
Previous 30,640
-0.0%
Holding current value
$68,020
Previous $759,000
9.49%
% of portfolio
0.32%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$29.2 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$23.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$22.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$12.4 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$11.7 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $215M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...